Home
GILD
GILD News

Latest Gilead Sciences Inc. (GILD) News on June 1, 2025

Gilead's Trodelvy, with Keytruda, cuts breast cancer risk by 35% in trial

Reuters

14 hours ago

Gilead's Trodelvy, with Keytruda, cuts breast cancer risk by 35% in trial

Trodelvy® Plus Keytruda® Reduces Risk of Disease Progression or Death by 35% Versus Keytruda and Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer

Business Wire

15 hours ago

Trodelvy® Plus Keytruda® Reduces Risk of Disease Progression or Death by 35% Versus Keytruda and Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer

Gilead Sciences Stock Gains 21% YTD: Buy, Sell or Hold?

Zacks

a day ago

Gilead Sciences Stock Gains 21% YTD: Buy, Sell or Hold?

Gilead Sciences Commemorated the Opening of the Bay Area Young Survivors Breast Cancer Memorial Garden

ACCESS Newswire

2 days ago

Gilead Sciences Commemorated the Opening of the Bay Area Young Survivors Breast Cancer Memorial Garden

Why Is Repligen (RGEN) Down 12.2% Since Last Earnings Report?

Zacks

2 days ago

Why Is Repligen (RGEN) Down 12.2% Since Last Earnings Report?

Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock

Zacks

3 days ago

Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock

GILD Announces Positive Data on Trodelvy in First-Line Breast Cancer

Zacks

6 days ago

GILD Announces Positive Data on Trodelvy in First-Line Breast Cancer

Gilead’s Phase III trial for breast cancer therapy meets primary goal

Clinical Trials Arena

6 days ago

Gilead’s Phase III trial for breast cancer therapy meets primary goal

Gilead Sciences, Inc. (GILD)’s Breast Cancer Study Success Drives Investor Optimism Amid Broader Market Slump

Insider Monkey

7 days ago

Gilead Sciences, Inc. (GILD)’s Breast Cancer Study Success Drives Investor Optimism Amid Broader Market Slump

Gilead announces ASCENT-03 study meets primary endpoint

TipRanks

8 days ago

Gilead announces ASCENT-03 study meets primary endpoint

MT Newswires

8 days ago

Gilead Sciences Insider Sold Shares Worth $3,010,564, According to a Recent SEC Filing

Gilead Sciences (NasdaqGS:GILD) Announces Promising Phase 3 Results For Trodelvy In Breast Cancer

Simply Wall St.

8 days ago

Gilead Sciences (NasdaqGS:GILD) Announces Promising Phase 3 Results For Trodelvy In Breast Cancer

Gilead (GILD) to Acquire HOOK for $10 million

Insider Monkey

8 days ago

Gilead (GILD) to Acquire HOOK for $10 million

MT Newswires

9 days ago

Gilead Sciences Says Trodelvy Met Primary Endpoint in Phase 3 Breast Cancer Trial

ASCENT-03: Trodelvy® Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement in Progression Free Survival in Patients With First-line Metastatic Triple-Negative Breast Cancer Who Are Not Candidates for Checkpoint Inhibitors

Business Wire

9 days ago

ASCENT-03: Trodelvy® Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement in Progression Free Survival in Patients With First-line Metastatic Triple-Negative Breast Cancer Who Are Not Candidates for Checkpoint Inhibitors

MT Newswires

9 days ago

HOOKIPA to Sell HBV, HIV Program Assets to Gilead; Shares Rise

Here's Why Gilead Sciences (GILD) is a Strong Value Stock

Zacks

11 days ago

Here's Why Gilead Sciences (GILD) is a Strong Value Stock

Gilead Sciences vs GSK: Which HIV Drugmaker is a Smarter Buy Now?

Zacks

11 days ago

Gilead Sciences vs GSK: Which HIV Drugmaker is a Smarter Buy Now?

Argus Research

12 days ago

Technical Assessment: Bullish in the Intermediate-Term

Gilead Sciences, Inc. (GILD) and Kite to Present Breakthrough Cancer Therapy Data at 2025 ASCO and EHA

Insider Monkey

13 days ago

Gilead Sciences, Inc. (GILD) and Kite to Present Breakthrough Cancer Therapy Data at 2025 ASCO and EHA

Gilead and Kite Announce Presentation of Transformative Data in 1L Metastatic Triple-Negative Breast Cancer, Updated Results in Multiple Myeloma and Early Data From Novel Investigational CAR T-Cell Therapy Targeting Brain Cancer at 2025 ASCO and EHA

Business Wire

16 days ago

Gilead and Kite Announce Presentation of Transformative Data in 1L Metastatic Triple-Negative Breast Cancer, Updated Results in Multiple Myeloma and Early Data From Novel Investigational CAR T-Cell Therapy Targeting Brain Cancer at 2025 ASCO and EHA

Gilead Sciences: Bringing PBC Into Focus Through Art of Patient Stories

ACCESS Newswire

17 days ago

Gilead Sciences: Bringing PBC Into Focus Through Art of Patient Stories

Is Trending Stock Gilead Sciences, Inc. (GILD) a Buy Now?

Zacks

17 days ago

Is Trending Stock Gilead Sciences, Inc. (GILD) a Buy Now?

Why Gilead Sciences (GILD) Is Among the Best Pharma Stocks to Invest in Amid the Domestic Manufacturing Boom

Insider Monkey

18 days ago

Why Gilead Sciences (GILD) Is Among the Best Pharma Stocks to Invest in Amid the Domestic Manufacturing Boom

Thermo Fisher, Biogen, Gilead Sciences, Moderna, and QuidelOrtho Stocks Trade Up, What You Need To Know

StockStory

19 days ago

Thermo Fisher, Biogen, Gilead Sciences, Moderna, and QuidelOrtho Stocks Trade Up, What You Need To Know

Trump expected to sign order to slash US drug prices

Yahoo Finance Video

19 days ago

Trump expected to sign order to slash US drug prices

The Zacks Analyst Blog Highlights Disney, Gilead Sciences, Eaton and Maui Land & Pineapple

Zacks

20 days ago

The Zacks Analyst Blog Highlights Disney, Gilead Sciences, Eaton and Maui Land & Pineapple

US-China trade truce, April CPI, drug prices: 3 Things

Yahoo Finance Video

20 days ago

US-China trade truce, April CPI, drug prices: 3 Things

GILD Q1 Earnings Call: HIV Growth and Pipeline Momentum Offset Revenue Miss

StockStory

20 days ago

GILD Q1 Earnings Call: HIV Growth and Pipeline Momentum Offset Revenue Miss

Is Gilead Sciences (GILD) Among the Best Stocks to Buy According to Jim Simons’ Renaissance Technologies?

Insider Monkey

20 days ago

Is Gilead Sciences (GILD) Among the Best Stocks to Buy According to Jim Simons’ Renaissance Technologies?

2 High-Yield Dividend Stocks to Buy in May and Hold Forever

Motley Fool

22 days ago

2 High-Yield Dividend Stocks to Buy in May and Hold Forever

Top Analyst Reports for Walt Disney, Gilead Sciences & Eaton

Zacks

22 days ago

Top Analyst Reports for Walt Disney, Gilead Sciences & Eaton

3 Value Stocks with Mounting Challenges

StockStory

23 days ago

3 Value Stocks with Mounting Challenges

Gilead reports final outcomes from trial of bulevirtide for chronic HDV

Clinical Trials Arena

24 days ago

Gilead reports final outcomes from trial of bulevirtide for chronic HDV

How To Put $100 In Your Retirement Fund Each Month With Gilead Sciences Stock

Benzinga

24 days ago

How To Put $100 In Your Retirement Fund Each Month With Gilead Sciences Stock

Gilead to Invest $11 Billion to Bolster Domestic Operations

The Wall Street Journal

24 days ago

Gilead to Invest $11 Billion to Bolster Domestic Operations

Investing.com

24 days ago

Gilead Sciences to invest $11 billion in U.S. R&D and manufacturing

Gilead boosts planned US investments by $11 billion amid tariff threat

Reuters

24 days ago

Gilead boosts planned US investments by $11 billion amid tariff threat

Gilead Sciences (NasdaqGS:GILD) Presents Promising Data On Livdelzi And Bulevirtide At EASL 2025

Simply Wall St.

24 days ago

Gilead Sciences (NasdaqGS:GILD) Presents Promising Data On Livdelzi And Bulevirtide At EASL 2025

Final Data From the Phase 3 MYR301 Study Demonstrated Longer Treatment With Bulevirtide Was Associated With Sustaining Undetectability After Stopping Treatment

Business Wire

25 days ago

Final Data From the Phase 3 MYR301 Study Demonstrated Longer Treatment With Bulevirtide Was Associated With Sustaining Undetectability After Stopping Treatment

Gilead’s Livdelzi® (Seladelpar) Demonstrated Consistent Efficacy and Safety Regardless of Prior Treatment History in New Data Presented at EASL 2025

Business Wire

25 days ago

Gilead’s Livdelzi® (Seladelpar) Demonstrated Consistent Efficacy and Safety Regardless of Prior Treatment History in New Data Presented at EASL 2025

Fighting the World's Most Devastating Diseases Is the Focus of This Installment of "The Centrifuge Sessions"

ACCESS Newswire

a month ago

Fighting the World's Most Devastating Diseases Is the Focus of This Installment of "The Centrifuge Sessions"

MT Newswires

a month ago

Mizuho Adjusts Price Target on Gilead Sciences to $117 From $100, Maintains Outperform Rating

Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term

Zacks

a month ago

Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term

Argus Research

a month ago

Analyst Report: Gilead Sciences, Inc.

Argus Research

a month ago

Market Digest: BAX, CAH, CCEP, EPD, EQIX, GILD, MCO, MGM, MSI, RJF, RTX, GM, META, APTV, XYZ

1 Profitable Stock on Our Watchlist and 2 to Turn Down

StockStory

a month ago

1 Profitable Stock on Our Watchlist and 2 to Turn Down

MT Newswires

a month ago

Wolfe Research Adjusts Gilead Sciences Price Target to $115 From $110

Gilead Sciences' (NASDAQ:GILD) Performance Is Even Better Than Its Earnings Suggest

Simply Wall St.

a month ago

Gilead Sciences' (NASDAQ:GILD) Performance Is Even Better Than Its Earnings Suggest

Should You Buy, Sell or Hold GILD Stock Post Q1 Earnings Miss?

Zacks

a month ago

Should You Buy, Sell or Hold GILD Stock Post Q1 Earnings Miss?

Is Most-Watched Stock Gilead Sciences, Inc. (GILD) Worth Betting on Now?

Zacks

a month ago

Is Most-Watched Stock Gilead Sciences, Inc. (GILD) Worth Betting on Now?

Gilead Sciences to Present at Upcoming Investor Conferences

Business Wire

a month ago

Gilead Sciences to Present at Upcoming Investor Conferences

MT Newswires

a month ago

Sector Update: Health Care Stocks Gain Late Afternoon

MT Newswires

a month ago

Sector Update: Health Care

MT Newswires

a month ago

Update: Gilead Sciences to Pay $202 Million in Settlement of Illegal Kickbacks Lawsuit

MT Newswires

a month ago

Gilead Sciences to Pay $202 Million in Settlement of Illegal Kickbacks Lawsuit

Gilead Sciences: AIDSVu Online Mapping Tool Helps Visualize HIV’s Impact in the United States

ACCESS Newswire

a month ago

Gilead Sciences: AIDSVu Online Mapping Tool Helps Visualize HIV’s Impact in the United States

Gilead to Present Latest Advancements Across Primary Biliary Cholangitis and Viral Hepatitis

Business Wire

a month ago

Gilead to Present Latest Advancements Across Primary Biliary Cholangitis and Viral Hepatitis

MT Newswires

a month ago

HSBC Adjusts Gilead Sciences Price Target to $93 From $82, Maintains Hold Rating

Wall Street’s New Tariff Safe Haven: High-Tax Biotech Stocks

The Wall Street Journal

a month ago

Wall Street’s New Tariff Safe Haven: High-Tax Biotech Stocks

Gilead Sciences First Quarter 2025 Earnings: Misses Expectations

Simply Wall St.

a month ago

Gilead Sciences First Quarter 2025 Earnings: Misses Expectations

Why Gilead Sciences Stock Slipped Today

Motley Fool

a month ago

Why Gilead Sciences Stock Slipped Today

Gilead Dives As Its Biggest Moneymaker Misses. Here's Why It Could Still Be A 'Safe Haven' Stock.

Investor's Business Daily

a month ago

Gilead Dives As Its Biggest Moneymaker Misses. Here's Why It Could Still Be A 'Safe Haven' Stock.

MT Newswires

a month ago

Gilead Delivers Lackluster Q1 Revenue on Trodelvy Miss, Oppenheimer Says

GILD Down on Q1 Earnings and Sales Miss, Oncology Sales Decline

Zacks

a month ago

GILD Down on Q1 Earnings and Sales Miss, Oncology Sales Decline

Gilead Sciences Stock Falls as Slumping COVID-19, Cancer Drug Sales Hit Revenue

Investopedia

a month ago

Gilead Sciences Stock Falls as Slumping COVID-19, Cancer Drug Sales Hit Revenue

MT Newswires

a month ago

Oppenheimer Adjusts Price Target on Gilead Sciences to $125 From $132, Maintains Outperform Rating

MT Newswires

a month ago

Goldman Sachs Adjusts Gilead Sciences Price Target to $100 From $97, Maintains Neutral Rating

Thomson Reuters StreetEvents

a month ago

Q1 2025 Gilead Sciences Inc Earnings Call

MT Newswires

a month ago

Morgan Stanley Raises Price Target on Gilead Sciences to $135 From $130, Keeps Overweight Rating

3 High Growth Tech Stocks Leading The US Market

Simply Wall St.

a month ago

3 High Growth Tech Stocks Leading The US Market

MT Newswires

a month ago

RBC Lifts Price Target on Gilead Sciences to $92 From $89, Keeps Sector Perform Rating

Argus Research

a month ago

Technical Assessment: Neutral in the Intermediate-Term

Morningstar Research

a month ago

Analyst Report: Gilead Sciences, Inc.

Gilead Sciences Earnings Were Solid. Why the Stock Is Dropping.

Barrons.com

a month ago

Gilead Sciences Earnings Were Solid. Why the Stock Is Dropping.

Gilead (GILD) Reports Q1 Earnings: What Key Metrics Have to Say

Zacks

a month ago

Gilead (GILD) Reports Q1 Earnings: What Key Metrics Have to Say

MT Newswires

a month ago

TD Cowen Adjusts Gilead Sciences Price Target to $110 From $100, Maintains Buy Rating

The Zacks Analyst Blog Highlights Gilead Sciences, Bristol Myers, Merck, AbbVie and Sanofi

Zacks

a month ago

The Zacks Analyst Blog Highlights Gilead Sciences, Bristol Myers, Merck, AbbVie and Sanofi

Gilead Sciences (GILD) To Report Earnings Tomorrow: Here Is What To Expect

StockStory

a month ago

Gilead Sciences (GILD) To Report Earnings Tomorrow: Here Is What To Expect

Gilead reports topline data from Phase III trial of Trodelvy combo therapy

Clinical Trials Arena

a month ago

Gilead reports topline data from Phase III trial of Trodelvy combo therapy

Is Gilead Sciences (GILD) a Cheap NASDAQ Stock to Buy According to Hedge Funds?

Insider Monkey

a month ago

Is Gilead Sciences (GILD) a Cheap NASDAQ Stock to Buy According to Hedge Funds?

Investing.com

a month ago

Cantor initiates coverage of U.S. large-cap pharma stocks: Gilead, AbbVie at Buy

Will These 5 Large Drug Maker Stocks Surpass Q1 Earnings Forecast?

Zacks

a month ago

Will These 5 Large Drug Maker Stocks Surpass Q1 Earnings Forecast?

Gilead Sciences (NasdaqGS:GILD) Reveals Promising Phase 3 Trial Results For Trodelvy In mTNBC

Simply Wall St.

a month ago

Gilead Sciences (NasdaqGS:GILD) Reveals Promising Phase 3 Trial Results For Trodelvy In mTNBC

MT Newswires

a month ago

Gilead Says Trodelvy-Keytruda Combination Improved Progression-Free Survival in Breast Cancer Study

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Zacks

a month ago

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Trodelvy® Plus Keytruda® Demonstrates a Statistically Significant and Clinically Meaningful Improvement in Progression Free Survival in Patients With Previously Untreated PD-L1+ Metastatic Triple-Negative Breast Cancer

Business Wire

a month ago

Trodelvy® Plus Keytruda® Demonstrates a Statistically Significant and Clinically Meaningful Improvement in Progression Free Survival in Patients With Previously Untreated PD-L1+ Metastatic Triple-Negative Breast Cancer

Here's Why Gilead Sciences (GILD) is a Strong Value Stock

Zacks

a month ago

Here's Why Gilead Sciences (GILD) is a Strong Value Stock

What Analyst Projections for Key Metrics Reveal About Gilead (GILD) Q1 Earnings

Zacks

a month ago

What Analyst Projections for Key Metrics Reveal About Gilead (GILD) Q1 Earnings

Should You Buy, Hold, or Sell GILD Stock Ahead of Q1 Earnings?

Zacks

a month ago

Should You Buy, Hold, or Sell GILD Stock Ahead of Q1 Earnings?

MT Newswires

a month ago

BMO Capital Adjusts Gilead Sciences Price Target to $120 From $115

MT Newswires

a month ago

Leerink Partners Adjusts Price Target on Gilead Sciences to $105 From $104, Keeps Outperform Rating

Gilead Sciences (GILD) Reports Next Week: Wall Street Expects Earnings Growth

Zacks

a month ago

Gilead Sciences (GILD) Reports Next Week: Wall Street Expects Earnings Growth

MT Newswires

a month ago

Nurix Says FDA Clears Oral IRAK4 Degrader Application for Inflammatory Diseases; Shares Up Pre-Bell

Gilead Sciences (GILD) Stock Moves -0.74%: What You Should Know

Zacks

a month ago

Gilead Sciences (GILD) Stock Moves -0.74%: What You Should Know

MT Newswires

a month ago

Gilead Sciences Insider Sold Shares Worth $266,000, According to a Recent SEC Filing

Gilead vs Bristol Myers: Which Biotech Bigwig is a Better Bet Now?

Zacks

a month ago

Gilead vs Bristol Myers: Which Biotech Bigwig is a Better Bet Now?

Is Gilead Sciences Inc. (NASDAQ:GILD) the Most Undervalued Quality Stock to Buy Now?

Insider Monkey

2 months ago

Is Gilead Sciences Inc. (NASDAQ:GILD) the Most Undervalued Quality Stock to Buy Now?

Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know

Zacks

2 months ago

Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know

MT Newswires

2 months ago

Goldman Sachs Adjusts Price Target on Gilead Sciences to $97 From $96, Maintains Neutral Rating

Share on Social Networks: